Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1389.55 with a total volume of ...

The anti-mRNA sentiment — coupled with the sweeping shake-up of science funding across the United States — has sparked fears ...

A new trial suggests a combination vaccine may offer equal or better protection against both flu and covid-19 compared to ...

Of course, a lot of upside could potentially be left on the table if MRNA shares really soar, which is why looking at the trailing twelve month trading history for Moderna Inc, as well as studying ...

Our premium News+ ad-free experience – only $10 more every 4 weeks!

HealthDay News — Urticaria is seen in association with experimental HIV-1 mRNA vaccination, according to a study published online April 29 in the Annals of Internal Medicine.

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

In the 20-year history of clinical trials for vaccines that ... A phase I trial was launched in 2019 for a therapeutic mRNA vaccine, which uses messenger RNA to instruct cells to produce tumour ...

The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a ...

The imperfections and risks of older vaccines became more evident as first-hand experience of their benefits waned, and ...

Scientists have uncovered a promising new way to enhance the effectiveness of vaccines by tapping into the potential of a specific type of immune cell, opening the door to long-lasting vaccines for ...